Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tipranavir

FDA-approved product (capsule, oral), marketed as Aptivus.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Tipranavir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hemorrhage
  • HIV infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Protease inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE09

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tipranavir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tipranavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects

    NCT00146328 · start 2001-04

    Registered record
    Registry ID
    NCT00146328
    Conditions
    HIV Infections
    Interventions
    Tipranavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2001-04
    Completion
    Not recorded
    Enrolment
    997

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTipranavir
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects

    NCT02251223 · start 2001-02

    Registered record
    Registry ID
    NCT02251223
    Conditions
    HIV Infections
    Interventions
    Tipranavir low dose; Tipranavir medium dose; Tipranavir high dose; Ritonavir low dose; Ritonavir high dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2001-02
    Completion
    Not recorded
    Enrolment
    208

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTipranavir low dose; Tipranavir medium dose; Tipranavir high dose; Ritonavir low dose +1 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Pharmacokinetics of Tipranavir Soft Elastic Capsules (SEDDS) and Ritonavir and Their Effects on Cytochrome P-450 (3A4) in Healthy Volunteers

    NCT02251132 · start 2000-10

    Registered record
    Registry ID
    NCT02251132
    Conditions
    Healthy
    Interventions
    TPV low 1; TPV low 2; TPV medium; TPV high 1; TPV high 2; RTV low; Ritonavir high; Radiolabelled erythromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2000-10
    Completion
    Not recorded
    Enrolment
    113

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTPV low 1; TPV low 2; TPV medium; TPV high 1 +4 more
    PhasePhase 1
    Registry statusCompleted

  • Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients

    NCT02239835 · start 1999-12

    Registered record
    Registry ID
    NCT02239835
    Conditions
    HIV Infections
    Interventions
    Tipranavir (TPV) low dose; Tipranavir (TPV) high dose; Ritonavir low dose; Ritonavir high dose; Saquinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    1999-12
    Completion
    Not recorded
    Enrolment
    79

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTipranavir (TPV) low dose; Tipranavir (TPV) high dose; Ritonavir low dose; Ritonavir high dose +1 more
    PhasePhase 2
    Registry statusTerminated

  • Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients

    NCT02238314 · start 1999-01

    Registered record
    Registry ID
    NCT02238314
    Conditions
    HIV Infections
    Interventions
    Tipranavir low dose; Tipranavir high dose; Ritonavir; Nucleoside Reverse Transcriptase Inhibitor (NRTI); Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-01
    Completion
    Not recorded
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTipranavir low dose; Tipranavir high dose; Ritonavir; Nucleoside Reverse Transcriptase Inhibitor (NRTI) +1 more
    PhasePhase 2
    Registry statusCompleted